News

News Dec 11, 2018 CardioCell and MedStar Heart & Vascular Institute Initiate Phase IIa Clinical Trial to Assess Stem Cell Therapy Effects in Heart Failure Patients With Left Ventricular Assist Devices (LVADs) FDA approves first study involving multiple intravenous injections of

News Dec 4, 2018 Innovative Stem Cell Therapeutic Strategy May be Transformative for Heart Failure Treatment Washington, D.C.,  – The FDA has recently approved an investigational new drug clinical trial that will start shortly at MedStar Heart & Vascular Institute. The trial,

News Apr 25, 2018 CardioCell, in Collaboration With MedStar, Plans Clinical Trial That May Transform Therapy for Terminal Heart Failure Patients SAN DIEGO — April 25, 2018 — CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that uses allogeneic stem cells for

News Apr 18, 2018 New Stem Cell Therapy May Transform Heart Failure Treatment Washington, D.C., April 18, 2018 – Clinical trial planning is underway at MedStar Heart & Vascular Institute to determine whether a novel stem cell therapy will improve heart function for patients with

News Nov 17, 2016 Positive Results From Study Sponsored by CardioCell Post in the American Heart Association’s Journal “Circulation Research” SAN DIEGO — Nov. 17, 2016 — Results from a study sponsored by CardioCell LLC, a global biotechnology company that uses allogeneic stem cells

News Oct 12, 2016 Independent Data Safety Monitoring Board (DSMB) Unanimously Recommends CardioCell’s Heart Failure Studies Continue SAN DIEGO – Oct. 12, 2016 – CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, announces an